Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Y-mAbs Therapeutics, Inc. - Common Stock (NQ:YMAB)

8.610 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Y-mAbs Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Earnings Outlook For Y-mAbs Therapeutics
 
Via Benzinga
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
Micro Marvel - Y-Mabs Therapeutics
Wall Street projected revenue will grow 26.00% this year and another 18.80% next year. Earnings are estimated to increase 68.90% this year but decrease 8.80% next year. 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Earnings Preview For Y-mAbs Therapeutics
 
Via Benzinga
4 Analysts Have This to Say About Y-mAbs Therapeutics
 
Via Benzinga
Analyst Expectations for Y-mAbs Therapeutics's Future
 
Via Benzinga
Where Y-mAbs Therapeutics Stands With Analysts
 
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know
 
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Preview: Y-mAbs Therapeutics's Earnings
 
Via Benzinga
Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility
Wedbush has upgraded Y-mAbs Therapeutics Inc (NASDAQ: YMAB)to Outperform from Neutral, with a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
 
Via Benzinga
Earnings Scheduled For May 8, 2023
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million. 
Via Benzinga
Earnings Outlook For Y-mAbs Therapeutics
 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
 
Via Benzinga
Crude Oil Rises 1.5%; Checkpoint Therapeutics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones jumping more than 200 points on Friday. The Dow traded up 0.72% to 33,095.32 while the NASDAQ rose 1.09% to 12,144.31. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead
The Dow Jones Industrial Average is boasting a triple-digit lead this afternoon, as investors unpack this morning's flood of inflation data. 
Via Talk Markets
Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 100 points on Friday. The Dow traded up 0.69% to 33,086.43 while the NASDAQ rose 1.01% to 12,134.43. The... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
Why Chicken Soup for the Soul Entertainment Shares Are Trading Lower By 30%; Here Are 20 Stocks Moving Premarket
Gainers Ault Alliance, Inc. (NASDAQ: AULT) jumped 34.8% to $0.1265 in pre-market trading. Ault Alliance plans share buyback of up to 333.33 million shares of common stock at $0.15 per share through... 
Via Benzinga
Earnings Scheduled For March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. 
Via Benzinga
YMAB FINAL DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Y-MABS THERAPEUTICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
From Kahn Swick & Foti, LLC
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 469 companies hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.